Douglas S. Ingram is the President and Chief Executive Officer of Sarepta Therapeutics, Inc., a position he has held since 2017. With a robust background in the biopharmaceutical industry, Ingram has been instrumental in guiding Sarepta towards its mission of developing transformative treatments for rare diseases. Before joining Sarepta, he served as President and CEO of Chase Pharmaceuticals Corporation, where he led the company's efforts to advance treatments for neurodegenerative diseases. His career also includes significant roles at Allergan, where he was Executive Vice President and Chief Administrative Officer, and at Valeant Pharmaceuticals, where he served as Executive Vice President and General Counsel. Ingram's leadership at Sarepta has been marked by several key achievements, including the successful development and commercialization of groundbreaking therapies for Duchenne muscular dystrophy (DMD). Under his guidance, Sarepta secured FDA approvals for multiple DMD treatments, significantly impacting the lives of patients and their families. His strategic vision has also propelled the company's expansion into other rare disease areas, fostering a robust pipeline of innovative therapies. Ingram's commitment to scientific excellence and patient-centric approaches has solidified Sarepta's position as a leader in the rare disease space. As CEO, Douglas S. Ingram plays a pivotal role in steering the company's overall direction and strategy. He is deeply involved in fostering collaborations with academic institutions, advocacy groups, and regulatory bodies to advance Sarepta's mission. Ingram's leadership style emphasizes transparency, innovation, and a relentless focus on delivering life-changing treatments to patients. His dedication to the rare disease community and his ability to navigate complex regulatory landscapes have been crucial to Sarepta's success and growth.